An international team of researchers has made a key discovery: Many children and young adults in Sub-Saharan Africa diagnosed with type 1 diabetes (T1D) may have a different form of the disease –one not caused by the immune system, unlike classic T1D. This discovery could change how diabetes is diagnosed, treated and managed across the region, paving the way for more accurate care and better outcomes.
The research was published today in Lancet Diabetes and Endocrinology.
“This is the first study across several Sub-Saharan African countries to use the same lab tests and genetic tools to learn more about type 1 diabetes. We’ve done similar research in the U.S. with different groups, but what’s exciting here is being able to compare results between Africa and the U.S.,” said the paper’s co-author Dana Dabelea, MD, PhD, Distinguished Professor and Associate Dean of Research at the Colorado School of Public Health on the University of Colorado Anschutz Medical Campus.
The researchers enrolled 894 participants with youth-onset diabetes from three African countries: Cameroon, Uganda and South Africa. They compared findings from this population with similar studies done in the U.S. in the same age range.
“It’s a really unique and important opportunity to explore the heterogeneity of T1D across countries and racial groups living in vastly different environments,” adds Dabelea, who is also the director of the Lifecourse Epidemiology of Adiposity and Diabetes (LEAD) Center at CU Anschutz.
Different form of T1D altogether
The researchers found that many young people in Sub-Saharan Africa diagnosed with T1D often don’t have the usual markers in their blood (called islet autoantibodies) typically seen in people with T1D in other parts of the world. Specifically, 65% of participants with T1D in this region did not have islet autoantibodies.
Islet autoantibodies help distinguish T1D from other forms of diabetes, like type 2 or monogenic diabetes, which have different causes and treatments.
“This suggests that many young people in this region have a different form of T1D altogether that is not autoimmune in origin,” said Dabelea.
When the researchers compared this data to studies in the U.S., they found a smaller but significant proportion (15%) of Black participants diagnosed with T1D had a similar form of diabetes found in Sub-Saharan Africa – characterized by negative autoantibodies and a low T1D genetic risk score.
However, white Americans with T1D showed the typical autoimmune pattern – even if they didn’t have detectable autoantibodies, their genetics still pointed to autoimmune diabetes.
“The identification of this T1D diabetes subtype in Sub-Saharan African populations and among individuals of African ancestry in the U.S. suggests a potential ancestral or genetic link,” Dabelea said. “These findings highlight the need to consider alternative etiologies in this group and a deeper understanding of the underlying mechanisms may provide important insights for future prevention and treatment strategies.”